Brentuximab vedotin (SNG35), made by attaching the antitublin agent monomethyl auristatin E (MMAE) to the CD30-specific monoclonal antibody cAC10, has been proved to be efficient in inducing durable objective responses and resulting in tumor regression for CD30-positive lymphomas with only mild-to-moderate toxic effects [25]–[26]. Here, TNFRSF8 is linked to neoplasm.